Video: Oral Upadacitinib Proves Effective for Adults, Adolescents with Atopic Dermatitis
Upadacitinib, a novel JAK inhibitor, induced clear or almost clear skin among many adults and adolescents with atopic dermatitis.
Emma Guttman-Yassky, MD, PhD, chair of the department of dermatology at the Icahn School of Medicine at Mount Sinai, spoke with MD/ alert about the research and the significant impact this drug could have on patients if approved.

Press Release
Mount Sinai Experts Author Landmark ‘Seminar’ on Atopic Dermatitis (Eczema) in The Lancet
Feb 13, 2025 View All Press Releases